Inhibition of SIRT1 signaling sensitizes the antitumor activity of silybin against human lung adenocarcinoma cells in vitro and in vivo

Molecular Cancer Therapeutics

Volumn 13, Issue 7, 2014, Pages 1860-1872

  Liang, Zhenxing ^a   Yang, Yang ^a   Wang, Haibin ^d   Yi, Wei ^a   Yan, Xiaolong ^b   Yan, Juanjuan ^c   Li, Yue ^a   Feng, Yingtong ^b   Yu, Shiqiang ^a   Yang, Jian ^a   Jin, Zhenxiao ^a   Duan, Weixun ^a   Chen, Wensheng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SILIBININ; SIRTUIN 1; SMALL INTERFERING RNA; ANTIOXIDANT; CASPASE 3; SILYMARIN;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ADHESION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; UPREGULATION; ADENOCARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; MALE; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; SCID MOUSE;

ADENOCARCINOMA; ANIMALS; ANTIOXIDANTS; APOPTOSIS; CASPASE 3; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; GLUTATHIONE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, NUDE; MICE, SCID; RANDOM ALLOCATION; REACTIVE OXYGEN SPECIES; RNA, SMALL INTERFERING; SILYMARIN; SIRTUIN 1; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904176537     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0942     Document Type: Article

References (40)

1. Chittezhath M, Deep G, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol Cancer Ther 2008;7:1817-26.
2. Yang Y, Yan X, Duan W, Yan J, Yi W, Liang Z, et al. Pterostilbene exerts antitumor activity via the Notch1 signaling pathway in human lung adenocarcinoma cells. PLoS ONE 2013;8:e62652.
3. Tyagi A, Singh RP, Ramasamy K, Raina K, Redente EF, Dwyer-Nield LD, et al. Growth inhibition and regression of lung tumors by silibinin: modulation of angiogenesis by macrophage-associated cytokines and nuclear factor-kappaB and signal transducers and activators of transcription 3. Cancer Prev Res 2009;2:74-83.
4. Singh RP, Deep G, Chittezhath M, Kaur M, Dwyer-Nield LD, Malkinson AM, et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 2006;98:846-55. (Pubitemid 43923441)
5. Wu JW, Lin LC, Tsai TH. Drug-drug interactions of silymarin on the perspective of pharmacokinetics. J Ethnopharmacol 2009;121:185-93.
6. Lin CM, Chen YH, Ma HP, Wang BW, Chiu JH, Chua SK, et al. Silibinin inhibits the invasion of IL-6-stimulated colon cancer cells via selective JNK/AP-1/MMP-2 modulation in vitro. J Agric Food Chem 2012;60:12451-7.
7. Brandon-Warner E, Eheim AL, Foureau DM, Walling TL, Schrum LW, McKillop IH. Silibinin (Milk Thistle) potentiates ethanol-dependent hepatocellular carcinoma progression in male mice. Cancer Lett 2012;326:88-95.
8. Liang L, Li L, Zeng J, Gao Y, Chen YL, Wang ZQ, et al. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep 2012;28:999-1005.
9. Yousefi M, Ghaffari SH, Soltani BM, Nafissi S, Momeny M, Zekri A, et al. Therapeutic efficacy of silibinin on human neuroblastoma cells: Akt and NF-κB expressions may play an important role in silibinin-induced response. Neurochem Res 2012;37:2053-63.
10. Lu W, Lin C, King TD, Chen H, Reynolds RC, Li Y. Silibinin inhibits Wnt/β-catenin signaling by suppressing Wnt co-receptor LRP6 expression in human prostate and breast cancer cells. Cell Signal 2012;24:2291-6.
11. Mateen S, Tyagi A, Agarwal C, Singh RP, Agarwal R. Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators. Mol Carcinog 2010;49:247-58.
12. Wang HJ, Tashiro S, Onodera S, Ikejima T. Inhibition of insulin-like growth factor 1 receptor signaling enhanced silibinin-induced activation of death receptor and mitochondrial apoptotic pathways in human breast cancer MCF-7 cells. J Pharmacol Sci 2008;107:260-9. (Pubitemid 352030312)
13. Corbi G, Conti V, Scapagnini G, Filippelli A, Ferrara N. Role of sirtuins, calorie restriction and physical activity in aging. Front Biosci 2012;4:768-78.
14. Rahman S, Islam R. Mammalian Sirt1: insights on its biological functions. Cell Commun Signal 2011;9:11.
15. Haigis MC, Sinclair DA. Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 2010;5:253-95.
16. Martinez-Pastor B, Mostoslavsky R. Sirtuins, metabolism, and cancer. Front Pharmacol 2012;3:22.
17. Roth M, Chen WY. Sorting out functions of sirtuins in cancer. Oncogene 2014;33:1609-20.
18. Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P, Sachchidanand. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun 2010;401:13-9.
19. Cheng Y, Cai L, Jiang P, Wang J, Gao C, Feng H, et al. SIRT1 inhibition by melatonin exerts antitumor activity in human osteosarcoma cells. Eur J Pharmacol 2013;715:219-29.
20. Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, et al. Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation. PLoS Genet 2006;2:e40.
21. Wang Q, Liu M, Liu WW, Hao WB, Tashiro S, Onodera S, et al. In vivo recovery effect of silibinin treatment on streptozotocin-induced diabetic mice is associated with the modulations of Sirt-1 expression and autophagy in pancreatic β-cell. J Asian Nat Prod Res 2012;14:413-23.
22. Zhou B, Wu LJ, Li LH, Tashiro S, Onodera S, Uchiumi F, et al. Silibinin protects against isoproterenol-induced rat cardiac myocyte injury through mitochondrial pathway after up-regulation of SIRT1. J Pharmacol Sci 2006;102:387-95. (Pubitemid 44954598)
23. Zhou B, Wu LJ, Tashiro S, Onodera S, Uchiumi F, Ikejima T. Silibinin protects rat cardiac myocyte from isoproterenol-induced DNA damage independent on regulation of cell cycle. Biol Pharm Bull 2006;29:1900-5. (Pubitemid 44338415)
24. Kauntz H, Bousserouel S, Gosse F, Marescaux J, Raul F. Silibinin, a natural fl avonoid, modulates the early expression of chemoprevention biomarkers in a preclinical model of colon carcinogenesis. Int J Oncol 2012;41:849-54.
25. Liu Y, Wang L, Wu Y, Lv C, Li X, Cao X, et al. Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway. Toxicology 2013;304:120-31.
26. Deep G, Agarwal R. Antimetastatic efficacy of silibinin: molecular mechanisms and therapeutic potential against cancer. Cancer Metastasis Rev 2010;29:447-63.
27. Post-White J, Ladas EJ, Kelly KM. Advances in the use of milk thistle (Silybum marianum). Integr Cancer Ther 2007;6:104-9. (Pubitemid 46871842)
28. Zhang Q, Zeng SX, Zhang Y, Zhang Y, Ding D, Ye Q, et al. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med 2012;4:298-312.
29. Suzuki K, Hayashi R, Ichikawa T, Imanishi S, Yamada T, Inomata M, et al. SRT1720, a SIRT1 activator, promotes tumor cell migration, and lung metastasis of breast cancer in mice. Oncol Rep 2012;27:1726-32.
30. Holloway KR, Barbieri A, Malyarchuk S, Saxena M, Nedeljkovic-Kurepa A, Cameron Mehl M, et al. SIRT1 positively regulates breast cancer associated human aromatase (CYP19A1) expression. Mol Endocrinol 2013;27:480-90.
31. Dixit D, Sharma V, Ghosh S, Mehta VS, Sen E. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition. Cell Death Dis 2012;3:e271.
32. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
33. Li L, Wang L, Li L, Wang Z, Ho Y, McDonald T, et al. Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib. Cancer Cell 2012;21:266-81.
34. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol 2007;8:275-83. (Pubitemid 46474662)
35. Tang Y, Zhao W, Chen Y, Zhao Y, Gu W. Acetylation is indispensable for p53 activation. Cell 2008;133:612-26. (Pubitemid 351636297)
36. Laemmle A, Lechleiter A, Roh V, Schwarz C, Portmann S, Furer C, et al. Inhibition of SIRT1 impairs the accumulation and transcriptional activity of HIF-1α protein under hypoxic conditions. PLoS ONE 2012;7:e33433.
37. Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006;66:4368-77.
38. Nguyen KC, Willmore WG, Tayabali AF. Cadmium telluride quantum dots cause oxidative stress leading to extrinsic and intrinsic apoptosis in hepatocellular carcinoma HepG2 cells. Toxicology 2013;306:114-23.
39. Adlakha YK, Saini N. miR-128 exerts pro-apoptotic effect in a p53 transcription-dependent and -independent manner via PUMA-Bak axis. Cell Death Dis 2013;4:e542.
40. Kang N, Zhang JH, Qiu F, Tashiro S, Onodera S, Ikejima T. Inhibition of EGFR signaling augments oridonin-induced apoptosis in human laryngeal cancer cells via enhancing oxidative stress coincident with activation of both the intrinsic and extrinsic apoptotic pathways. Cancer Lett 2010;294:147-58.